Abstract
The number of people living with diabetes, the number of deaths attributable to it, and the cost of treating the disease and its complications are increasing exponentially. Centuries of research led to the discovery of insulin and other drugs based on pathophysiology from “the triumvirate to ominous octet”. The agonists of the glucagon-like peptide-1 (GLP-1) receptor, and the inhibitors of the sodium-glucose transport protein 2 (SGLT2) are the new drugs that improve cardiovascular outcomes and provide renal protection, and they are being used increasingly for evidence-based treatment of type 2 diabetes. Bariatric surgery, when indicated, results in excellent weight- and metabolic-control, and in many instances even remission of diabetes. Technological advances like Flash glucose monitoring, continuous subcutaneous insulin infusion (CSII), and continuous glucose monitoring (CGM) have improved glycemic control, reduced episodes of severe hypoglycemia, and improved quality of life. For the treatment of diabetic macular edema intravitreal injection of several anti-VEGF agents are being used. Numerous people living in the middle- and low-income countries cannot afford the costs of care of diabetes. Institutions like the World Health Organization, the World Bank and the International Monetary Fund should roll out plans to convince the politicians to invest more in improving the diabetes care facilities.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
American Diabetes Association (2020a) 14. Management of diabetes in pregnancy: standards of medical care in diabetes-2020. Diabetes Care 43(Suppl 1):S183–SS92
American Diabetes Association (2020b) 8. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes-2020. Diabetes Care 43(Suppl 1):S89–S97
Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R et al (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387(10019):679–690
Behboudi-Gandevani S, Amiri M, Bidhendi Yarandi R, Ramezani TF (2019) The impact of diagnostic criteria for gestational diabetes on its prevalence: a systematic review and meta-analysis. Diabetol Metab Syndr 11:11
Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C et al (2020) 2019 update to: Management of Hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care 43(2):487–493
Buteau J (2008) GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival. Diabetes Metab 34(Suppl 2):S73–S77
Drucker DJ, Habener JF, Holst JJ (2017) Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest 127(12):4217–4227
Gill RS, Birch DW, Shi X, Sharma AM, Karmali S (2010) Sleeve gastrectomy and type 2 diabetes mellitus: a systematic review. Surg Obes Relat Dis 6(6):707–713
Greene JA, Riggs KR (2015) Why is there no generic insulin? Historical origins of a modern problem. N Engl J Med 372(12):1171–1175
Group HSCR (2009) Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: associations with neonatal anthropometrics. Diabetes 58(2):453–459
Helmstadter J, Frenis K, Filippou K, Grill A, Dib M, Kalinovic S et al (2020) Endothelial GLP-1 (glucagon-like peptide-1) receptor mediates cardiovascular protection by Liraglutide in mice with experimental arterial hypertension. Arterioscler Thromb Vasc Biol 40(1):145–158
Manne-Goehler J, Geldsetzer P, Agoudavi K, Andall-Brereton G, Aryal KK, Bicaba BW et al (2019) Health system performance for people with diabetes in 28 low- and middle-income countries: a cross-sectional study of nationally representative surveys. PLoS Med 16(3):e1002751
Mohan V, Khunti K, Chan SP, Filho FF, Tran NQ, Ramaiya K et al (2020) Management of Type 2 diabetes in developing countries: balancing optimal glycaemic control and outcomes with affordability and accessibility to treatment. Diabetes Ther 11(1):15–35
Moucheraud C, Lenz C, Latkovic M, Wirtz VJ (2019) The costs of diabetes treatment in low- and middle-income countries: a systematic review. BMJ Glob Health 4(1):e001258
Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L et al (2019) SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7(11):845–854
Patterson CC, Karuranga S, Salpea P, Saeedi P, Dahlquist G, Soltesz G et al (2019) Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 157:107842
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N et al (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract 157:107843
Saeedi P, Salpea P, Karuranga S, Petersohn I, Malanda B, Gregg EW et al (2020) Mortality attributable to diabetes in 20–79 years old adults, 2019 estimates: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 162:108086
Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS et al (2017) Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica 237(4):185–222
The Lancet Diabetes E (2020) Action on improving access to insulin. Lancet Diabetes Endocrinol 8(1):1
Umapathysivam MM, Lee MY, Jones KL, Annink CE, Cousins CE, Trahair LG et al (2014) Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes 63(2):785–790
Vick H, Diedrich DF, Baumann K (1973) Reevaluation of renal tubular glucose transport inhibition by phlorizin analogs. Am J Phys 224(3):552–557
Williams R, Karuranga S, Malanda B, Saeedi P, Basit A, Besancon S et al (2020) Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 162:108072
Yuen L, Saeedi P, Riaz M, Karuranga S, Divakar H, Levitt N et al (2019) Projections of the prevalence of hyperglycaemia in pregnancy in 2019 and beyond: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 157:107841
Acknowledgement
Financial support was obtained from the Karolinska Institutet and the Uppsala County Council.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Islam, M.S. (2020). Diabetes: From Research to Clinical Practice. In: Islam, M.S. (eds) Diabetes: from Research to Clinical Practice. Advances in Experimental Medicine and Biology(), vol 1307. Springer, Cham. https://doi.org/10.1007/5584_2020_553
Download citation
DOI: https://doi.org/10.1007/5584_2020_553
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-51088-6
Online ISBN: 978-3-030-51089-3
eBook Packages: MedicineMedicine (R0)